Monitoring trilostane treatment in dogs with pituitary

Abstract

BACKGROUND: The effectiveness of trilostane treatment is currently monitored by regular ACTH stimulation tests, which are time-consuming and expensive. Therefore, a monitoring system without a stimulation protocol and with less client expense would be preferable. HYPOTHESIS/OBJECTIVES: The aim of our study was to evaluate if baseline cortisol, endogenous ACTH (ACTH) concentration or the baseline cortisol to ACTH ratio (cortisol/ACTH ratio) could replace the ACTH stimulation test. ANIMALS: Forty trilostane-treated dogs with pituitary-dependent hypercortisolism (PDH) were included in this prospective study. METHODS: A total of 148 ACTH stimulation tests and 77 ACTH concentrations and cortisol/ACTH ratios were analyzed. Control of cortisol release was classified according to cortisol concentration after ACTH administration as excessive (<1.5 &#x3bc;g/dL; group 1), adequate (1.5-5.4 &#x3bc;g/dL; group 2), or inadequate (>5.4 &#x3bc;g/dL; group 3). RESULTS: Baseline cortisol concentrations had considerable overlap between excessively, adequately, and inadequately controlled dogs. Only baseline cortisol >4.4 &#x3bc;g/dL (in 12% of tests) was a reliable diagnosis of inadequate control. Endogenous ACTH concentrations did not differ between groups. The overlap of the cortisol/ACTH ratio between groups was large. Correct classification was only possible if the cortisol/ACTH ratio was >15, which occurred in 4% of tests. CONCLUSIONS AND CLINICAL IMPORTANCE: To monitor trilostane treatment the ACTH stimulation test cannot be replaced by baseline cortisol, ACTH concentration, or the cortisol/ACTH ratio.